protein

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39

MBS142617

0.1 mg

225 USD

Recombinant Protein

Recombinant HIV-1 Envelope conjugated to HIV-2 gp39

HIV-1 Envelope conjugated to HIV-2 gp39

HIV-1, 2; HIV-1 envelope conjugated to HIV-2 gp39 Recombinant; HIV-1,2

E Coli

Immunoreactive with all sera of HIV-1, HIV type O & HIV-2 infected individuals.

Greater than 95.0% as determined by HPLC analysis and SDS-PAGE.

100 mM Na-PO4, pH 6 & 0.05% SDS. Sterile filtered colorless clear solution.

ELISA (EIA), Western Blot (WB)

HIV-1,2 antigen is suitable for ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.

VIRAL ANTIGENS- HUMAN IMMUNODEFICIENCY VIRUS; Viral Antigens; HIV

Description: HIV-1,2 recombinant- E Coli derived recombinant 27 kDa protein contains the C- terminus of gp120 and most of gp41. The protein is conjugated to a 23 amino acids synthetic peptide derived from gp39 of HIV-2. Introduction: HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids.Immunodeficiency develops more slowly with HIV-2.HIV-2 is less infectious in the early stages of the virus than with HIV-1.The infectiousness of HIV-2 increases as the virus progresses.Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion.HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25 degree C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition.

0.1 mg

225 USD